 Connection
Steven Ojemann to Parkinson Disease
This is a "connection" page, showing publications Steven Ojemann has written about Parkinson Disease.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.777 |
|
|
|
-
Baumgartner AJ, Thompson JA, Kern DS, Ojemann SG. Novel targets in deep brain stimulation for movement disorders. Neurosurg Rev. 2022 Aug; 45(4):2593-2613.
Score: 0.518
-
Kortz MW, Kongs BM, McCray E, Grassia F, Hosokawa P, Bernstein JE, Moore SP, Yanovskaya M, Ojemann SG. How neuropsychiatric comorbidity, modulatory indication, demographics, and other factors impact deep brain stimulation inpatient outcomes in the United States: A population-based study of 27,956 patients. Clin Neurol Neurosurg. 2021 Sep; 208:106842.
Score: 0.490
-
Bayman E, Chee K, Mendlen M, Denman DJ, Tien RN, Ojemann S, Kramer DR, Thompson JA. Subthalamic nucleus synchronization between beta band local field potential and single-unit activity in Parkinson's disease. Physiol Rep. 2024 May; 12(9):e16001.
Score: 0.149
-
Radcliffe EM, Baumgartner AJ, Kern DS, Al Borno M, Ojemann S, Kramer DR, Thompson JA. Oscillatory beta dynamics inform biomarker-driven treatment optimization for Parkinson's disease. J Neurophysiol. 2023 06 01; 129(6):1492-1504.
Score: 0.139
-
Lewis S, Radcliffe E, Ojemann S, Kramer DR, Hirt L, Case M, Holt-Becker AB, Raike R, Kern DS, Thompson JA. Pilot Study to Investigate the Use of In-Clinic Sensing to Identify Optimal Stimulation Parameters for Deep Brain Stimulation Therapy in Parkinson's Disease. Neuromodulation. 2024 Apr; 27(3):509-519.
Score: 0.137
-
Kennis M, Hale EW, Hemendinger E, Davis R, Ojemann SG, Strom L, Klepitskaya O. Suicide in Deep Brain Stimulation for Parkinson's Disease: A Retrospective Case-Control Study. J Parkinsons Dis. 2023; 13(3):415-419.
Score: 0.135
-
Tekriwal A, Baker S, Christensen E, Petersen-Jones H, Tien RN, Ojemann SG, Kern DS, Kramer DR, Felsen G, Thompson JA. Quantifying neuro-motor correlations during awake deep brain stimulation surgery using markerless tracking. Sci Rep. 2022 10 27; 12(1):18120.
Score: 0.134
-
Baker S, Tekriwal A, Felsen G, Christensen E, Hirt L, Ojemann SG, Kramer DR, Kern DS, Thompson JA. Automatic extraction of upper-limb kinematic activity using deep learning-based markerless tracking during deep brain stimulation implantation for Parkinson's disease: A proof of concept study. PLoS One. 2022; 17(10):e0275490.
Score: 0.134
-
Kern D, Korsmo M, Baumgartner AJ, Kramer D, Ojemann S, Case M, Holt-Becker AB, Raike R, Thompson JA. Methylphenidate effects on a clinically informative oscillatory signal within the subthalamic nucleus in Parkinson's disease during deep brain stimulation programming. Brain Stimul. 2022 May-Jun; 15(3):747-749.
Score: 0.129
-
Tekriwal A, Felsen G, Ojemann SG, Abosch A, Thompson JA. Motor context modulates substantia nigra pars reticulata spike activity in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2022 04; 93(4):386-394.
Score: 0.128
-
Thaker AA, Reddy KM, Thompson JA, Gerecht PD, Brown MS, Abosch A, Ojemann SG, Kern DS. Coronal Gradient Echo MRI to Visualize the Zona Incerta for Deep Brain Stimulation Targeting in Parkinson's Disease. Stereotact Funct Neurosurg. 2021; 99(5):443-450.
Score: 0.121
-
Kern DS, Fasano A, Thompson JA, Abosch A, Ojemann S, Munhoz RP. Constant Current versus Constant Voltage: Clinical Evidence Supporting a Fundamental Difference in the Modalities. Stereotact Funct Neurosurg. 2021; 99(2):171-175.
Score: 0.117
-
Kern DS, Uy D, Rhoades R, Ojemann S, Abosch A, Thompson JA. Discrete changes in brain volume after deep brain stimulation in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2020 09; 91(9):928-937.
Score: 0.114
-
Thompson JA, Yin D, Ojemann SG, Abosch A. Use of the Putamen as a Surrogate Anatomical Marker for the Internal Segment of the Globus Pallidus in Deep Brain Stimulation Surgery. Stereotact Funct Neurosurg. 2017; 95(4):229-235.
Score: 0.093
-
Niethammer M, Tang CC, LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Sapan CV, Eidelberg D, During MJ, Kaplitt MG, Feigin A. Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson's disease. JCI Insight. 2017 04 06; 2(7):e90133.
Score: 0.091
-
Davis RA, Epstein CH, Klepitskaya O, Sharp CS, Ojemann S, Abosch A, Heru AM. Disambiguating the Psychiatric Sequelae of Parkinson's Disease, Deep Brain Stimulation, and Life Events: Case Report and Literature Review. Am J Psychiatry. 2017 Jan 01; 174(1):11-15.
Score: 0.089
-
LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Van Meter L, Sapan CV, During MJ, Kaplitt MG, Feigin A. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 2011 Apr; 10(4):309-19.
Score: 0.060
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|